Towards Healthcare
Biopharmaceutical Contract Manufacturing Market Hits USD 115.65 Bn by 2034

Biopharmaceutical Contract Manufacturing Market Poised for Growth by 2034 Amid Rising Demand for Cell Therapies & Oncology Drugs

According to market projections, the global biopharmaceutical contract manufacturing market, valued at USD 40.14 billion in 2024, is anticipated to reach USD 115.65 billion by 2034, growing at a CAGR of 11.14% over the next decade.The biopharmaceutical contract manufacturing market is growing due to contract manufacturers making significant investments in modern machinery and advanced technology. It offers companies effective and affordable solutions for scaling up production while maintaining high-quality standards and regulatory compliance. North America is dominant due to the presence of a large number of biomanufacturing facilities and development in manufacturing technologies.

  • Insight Code: 5950
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

The biopharmaceutical contract manufacturing market is projected to reach USD 115.65 billion by 2034, growing at a CAGR of 11.14% from 2024 to 2034.

North America is currently leading the biopharmaceutical contract manufacturing market due to the presence of a skilled workforce and leading CDMOs.

The Biopharmaceutical contract manufacturing market includes eight segments such as by product type, by manufacturing type, by technology, by service type, by scale of operation, by therapeutic area, by end user, and by region.

Key trends include a surge in cell and gene therapy manufacturing and increased outsourcing of complex biologics production.

The process is roughly divided into a cultivation process, a purification process, and a formulation process. Pharmaceutical ingredients are processed into formulations, such as injections and internal medicines, in the subsequent formulation process.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.